Adherence to Treatment in Allergic Rhinitis During the Pollen Season in Europe: A MASK‐air Study

ABSTRACT Background Adherence to rhinitis treatment has been insufficiently assessed. We aimed to use data from the MASK‐air mHealth app to assess adherence to oral antihistamines (OAH), intra‐nasal corticosteroids (INCS) or azelastine‐fluticasone in patients with allergic rhinitis. Methods We inclu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical and experimental allergy Jg. 55; H. 3; S. 226 - 238
Hauptverfasser:	Sousa‐Pinto, Bernardo, Costa, Elísio M., Vieira, Rafael José, Pfaar, Oliver, Bedbrook, Anna, Amaral, Rita, Brussino, Luisa, Kvedariene, Violeta, Larenas‐Linnemann, Desiree E., Iinuma, Tomohisa, Pham‐Thi, Nhân, Regateiro, Frederico S., Taborda‐Barata, Luis, Ventura, Maria Teresa, Ansotegui, Ignacio J., Bergmann, Karl C., Canonica, G. Walter, Cardona, Victoria, Cecchi, Lorenzo, Cherrez‐Ojeda, Ivan, Cingi, Cemal, Cruz, Alvaro A., Del Giacco, Stefano, Devillier, Philippe, Fokkens, Wytske J., Gemicioglu, Bilun, Ivancevich, Juan Carlos, Kuna, Piotr, Louis, Renaud, Makris, Michael, Morais‐Almeida, Mario, Niedoszytko, Marek, Papadopoulos, Nikolaos G., Pereira, Ana Margarida, Reitsma, Sietze, Robles‐Velasco, Karla, Rouadi, Philip W., Samolinski, Boleslaw, Sova, Milan, Toppila‐Salmi, Sanna K., Sastre, Joaquin, Valiulis, Arunas, Yorgancioglu, Arzu, Zidarn, Mihaela, Zuberbier, Torsten, Fonseca, Joao A., Bousquet, Jean, Anto, Josep M., Kupczyk, Maciej, Kulus, Marek, Roche, Nicolas, Scichilone, Nicola, Almeida, Rute, Bosnic‐Anticevich, Sinthia, Loureiro, Claudia Chaves, Vries, Govert, Giuliano, Antonio F. M., Jácome, Cristina, Kaidashev, Igor, Louis, Gilles, Lourenço, Olga, Makela, Mika, Mullol, Joaquim, O’Hehir, Robyn, Okamoto, Yoshitaka, Olze, Heidi, Romantowski, Jan, Rivero‐Yeverino, Daniela, Rodriguez‐Gonzalez, Monica, Savouré, Marine, Serpa, Faradiba S., Sheikh, Aziz, Sofiev, Mikhail, Sperl, Annette, Todo‐Bom, Ana, Tsiligianni, Ioanna, Valovirta, Erkka, Eerd, Michiel, Blain, Hubert, Boulet, Louis‐Philippe, Brusselle, Guy, Buhl, Roland, Charpin, Denis, Casale, Thomas, Chivato, Tomas, Correia‐de‐Sousa, Jaime, Corrigan, Christopher, Blay, Frédéric, Dykewicz, Mark, Fiocchi, Alessandro, Giovannini, Mattia, Jutel, Marek, Keil, Thomas, La Grutta, Stefania, Lipworth, Brian, Papi, Alberto, Cordeiro, Carlos Robalo, Torres, Maria J., Usmani, Omar S., Brightling, Christopher
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England Wiley Subscription Services, Inc 01.03.2025 John Wiley and Sons Inc
Schlagworte:	Adolescent Adrenal Cortex Hormones - administration & dosage Adrenal Cortex Hormones - therapeutic use Adult Allergic rhinitis Anti-Allergic Agents - therapeutic use Antihistamines Asthma Corticosteroids Europe - epidemiology Female Fluticasone Hay fever Histamine Antagonists - administration & dosage Histamine Antagonists - therapeutic use Humans Male Medication Adherence Middle Aged Missing data mobile health Original Phthalazines - therapeutic use Pollen Pollen - adverse effects Pollen - immunology Rhinitis Rhinitis, Allergic - drug therapy Rhinitis, Allergic - epidemiology Rhinitis, Allergic, Seasonal - drug therapy Rhinitis, Allergic, Seasonal - epidemiology Seasons Sensitivity analysis Surveys and Questionnaires treatment adherence Young Adult Europe mobile health treatment adherence allergic rhinitis
ISSN:	0954-7894, 1365-2222, 1365-2222
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	ABSTRACT Background Adherence to rhinitis treatment has been insufficiently assessed. We aimed to use data from the MASK‐air mHealth app to assess adherence to oral antihistamines (OAH), intra‐nasal corticosteroids (INCS) or azelastine‐fluticasone in patients with allergic rhinitis. Methods We included regular European MASK‐air users with self‐reported allergic rhinitis and reporting at least 1 day of OAH, INCS or azelastine‐fluticasone. We assessed weeks during which patients answered the MASK‐air questionnaire on all days. We restricted our analyses to data provided between January and June, to encompass the pollen seasons across the different assessed countries. We analysed symptoms using visual analogue scales (VASs) and the combined symptom‐medication score (CSMS), performing stratified analyses by weekly adherence levels. Medication adherence was computed as the proportion of days in which patients reported rhinitis medication use. Sensitivity analyses were performed considering all weeks with at most 1 day of missing data and all months with at most 4 days of missing data. Results We assessed 8212 complete weeks (1361 users). Adherence (use of medication > 80% days) to specific drug classes ranged from 31.7% weeks for azelastine‐fluticasone to 38.5% weeks for OAH. Similar adherence to rhinitis medication was found in users with or without self‐reported asthma, except for INCS (better adherence in asthma patients). VAS and CSMS levels increased from no adherence to full adherence, except for INCS. A higher proportion of days with uncontrolled symptoms was observed in weeks with higher adherence. In full adherence weeks, 41.2% days reported rhinitis co‐medication. The sensitivity analyses displayed similar results. Conclusions A high adherence was found in patients reporting regular use of MASK‐air. Different adherence patterns were found for INCS compared to OAH or azelastine‐fluticasone that are likely to impact guidelines. In a study assessing mobile health data, (i) adherence to rhinitis medication was highest for oral antihistamines and lowest for azelastine‐fluticasone, (ii) in weeks of partial adherence, azelastine‐fluticasone was associated with lower levels of reported rhinitis symptoms than other medication classes.
Bibliographie:	None for this specific study. MASK‐air has been supported by EU grants (from the Impact of air Pollution on Asthma and Rhinitis project of the European Institute of Innovation and Technology Health; Structural and Development Funds, Région Languedoc Roussillon, and Provence‐Alpes‐Côte d'Azur; Twinning, European Innovation Partnership on Active and Healthy Ageing, DG Santé and DG Connect; H2020 and Horizon Europe), Universidad Espíritu Santo, Samborondón, Ecuador, University of Liège and educational grants from Mylan‐Viatris, Allergologisk Laboratorium København, GlaxoSmithKline, Novartis, Stallergènes‐Greer, and Noucor. Funding A list of the think tank members appears in the ‘The MASK‐air think tank’ section. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Funding: None for this specific study. MASK‐air has been supported by EU grants (from the Impact of air Pollution on Asthma and Rhinitis project of the European Institute of Innovation and Technology Health; Structural and Development Funds, Région Languedoc Roussillon, and Provence‐Alpes‐Côte d'Azur; Twinning, European Innovation Partnership on Active and Healthy Ageing, DG Santé and DG Connect; H2020 and Horizon Europe), Universidad Espíritu Santo, Samborondón, Ecuador, University of Liège and educational grants from Mylan‐Viatris, Allergologisk Laboratorium København, GlaxoSmithKline, Novartis, Stallergènes‐Greer, and Noucor.
ISSN:	0954-7894 1365-2222 1365-2222
DOI:	10.1111/cea.70004